SALIX PHARMACEUTICALS, LTD. v. NORWICH PHARMACEUTICALS., INC. Before Lourie, Chen, and Cunningham. Appeal from the District of Delaware Summary: The Federal Circuit ruled that an ANDA listing an infringing indication cannot...more
Federal Circuit Summaries -
Before Newman, Dyk, and Chen. Appeal from the Patent Trial and Appeal Board.
Summary: An injury-in-fact is required to establish Article III standing for judicial review of agency action,...more
2/12/2019
/ Appeals ,
Article III ,
Biosimilars ,
Clinical Trials ,
Estoppel ,
Injury-in-Fact ,
Inter Partes Review (IPR) Proceeding ,
Mootness ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Standing
Federal Circuit Summaries -
Before Dyk, Wallach, and Hughes. Appeal from the United States District Court for the District of Delaware.
Summary: A distribution agreement qualifies as an invalidating “offer for sale”...more
2/7/2018
/ Abbreviated New Drug Application (ANDA) ,
Appeals ,
Generic Drugs ,
Hospira ,
Offers ,
On-Sale Bar ,
Patents ,
Pharmaceutical Patents ,
Remand ,
Reversal ,
Sales & Distribution Agreements